These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 23630346)
41. Acquisition of resistance to trastuzumab in gastric cancer cells is associated with activation of IL-6/STAT3/Jagged-1/Notch positive feedback loop. Yang Z; Guo L; Liu D; Sun L; Chen H; Deng Q; Liu Y; Yu M; Ma Y; Guo N; Shi M Oncotarget; 2015 Mar; 6(7):5072-87. PubMed ID: 25669984 [TBL] [Abstract][Full Text] [Related]
42. Spontaneous and pronase-induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines. Recupero D; Daniele L; Marchiò C; Molinaro L; Castellano I; Cassoni P; Righi A; Montemurro F; Sismondi P; Biglia N; Viale G; Risio M; Sapino A J Pathol; 2013 Feb; 229(3):390-9. PubMed ID: 22806884 [TBL] [Abstract][Full Text] [Related]
43. Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab. Magnifico A; Albano L; Campaner S; Delia D; Castiglioni F; Gasparini P; Sozzi G; Fontanella E; Menard S; Tagliabue E Clin Cancer Res; 2009 Mar; 15(6):2010-21. PubMed ID: 19276287 [TBL] [Abstract][Full Text] [Related]
44. MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition. Astanehe A; Finkbeiner MR; Krzywinski M; Fotovati A; Dhillon J; Berquin IM; Mills GB; Marra MA; Dunn SE Oncogene; 2012 Oct; 31(41):4434-46. PubMed ID: 22249268 [TBL] [Abstract][Full Text] [Related]
45. HER2 interacts with CD44 to up-regulate CXCR4 via epigenetic silencing of microRNA-139 in gastric cancer cells. Bao W; Fu HJ; Xie QS; Wang L; Zhang R; Guo ZY; Zhao J; Meng YL; Ren XL; Wang T; Li Q; Jin BQ; Yao LB; Wang RA; Fan DM; Chen SY; Jia LT; Yang AG Gastroenterology; 2011 Dec; 141(6):2076-2087.e6. PubMed ID: 21925125 [TBL] [Abstract][Full Text] [Related]
46. HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer. Sampera A; Sánchez-Martín FJ; Arpí O; Visa L; Iglesias M; Menéndez S; Gaye É; Dalmases A; Clavé S; Gelabert-Baldrich M; Poulsen TT; Kragh M; Bellosillo B; Albanell J; Rovira A; Montagut C Mol Cancer Ther; 2019 Nov; 18(11):2135-2145. PubMed ID: 31484705 [TBL] [Abstract][Full Text] [Related]
47. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Nagy P; Friedländer E; Tanner M; Kapanen AI; Carraway KL; Isola J; Jovin TM Cancer Res; 2005 Jan; 65(2):473-82. PubMed ID: 15695389 [TBL] [Abstract][Full Text] [Related]
48. Trastuzumab Inhibits Growth of HER2-Negative Gastric Cancer Cells Through Gastrin-Initialized CCKBR Signaling. Cui Y; Li SB; Peng XC; Wu J; Fu GH Dig Dis Sci; 2015 Dec; 60(12):3631-41. PubMed ID: 26173505 [TBL] [Abstract][Full Text] [Related]
49. Understanding resistance to endocrine agents: molecular mechanisms and potential for intervention. Sabnis G; Brodie A Clin Breast Cancer; 2010 Feb; 10(1):E6-E15. PubMed ID: 20133251 [TBL] [Abstract][Full Text] [Related]
50. Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer. Lesniak D; Xu Y; Deschenes J; Lai R; Thoms J; Murray D; Gosh S; Mackey JR; Sabri S; Abdulkarim B Cancer Res; 2009 Nov; 69(22):8620-8. PubMed ID: 19887601 [TBL] [Abstract][Full Text] [Related]
51. A Her2-let-7-β2-AR circuit affects prognosis in patients with Her2-positive breast cancer. Liu D; Deng Q; Sun L; Wang T; Yang Z; Chen H; Guo L; Liu Y; Ma Y; Guo N; Shi M BMC Cancer; 2015 Nov; 15():832. PubMed ID: 26526356 [TBL] [Abstract][Full Text] [Related]
52. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. du Manoir JM; Francia G; Man S; Mossoba M; Medin JA; Viloria-Petit A; Hicklin DJ; Emmenegger U; Kerbel RS Clin Cancer Res; 2006 Feb; 12(3 Pt 1):904-16. PubMed ID: 16467105 [TBL] [Abstract][Full Text] [Related]
53. Advanced HER2-positive gastric cancer: current and future targeted therapies. Pazo Cid RA; Antón A Crit Rev Oncol Hematol; 2013 Mar; 85(3):350-62. PubMed ID: 23021388 [TBL] [Abstract][Full Text] [Related]
54. Evaluation of Trastuzumab Anti-Tumor Efficacy and its Correlation with HER-2 Status in Patient-Derived Gastric Adenocarcinoma Xenograft Models. Chen H; Ye Q; Lv J; Ye P; Sun Y; Fan S; Su X; Gavine P; Yin X Pathol Oncol Res; 2015 Sep; 21(4):947-55. PubMed ID: 25749810 [TBL] [Abstract][Full Text] [Related]
55. β2-AR-induced Her2 transactivation mediated by Erbin confers protection from apoptosis in cardiomyocytes. Shi M; Zhao M; Hu M; Liu D; Cao H; Qian L; Yang Z; Hu Y; Yu M; Yang S; Ma Y; Guo N Int J Cardiol; 2013 Aug; 167(4):1570-7. PubMed ID: 22564389 [TBL] [Abstract][Full Text] [Related]
56. Upregulation of the splice variant MUC4/Y in the pancreatic cancer cell line MIA PaCa-2 potentiates proliferation and suppresses apoptosis: new insight into the presence of the transcript variant of MUC4. Xie K; Zhi X; Tang J; Zhu Y; Zhang J; Li Z; Tao J; Xu Z Oncol Rep; 2014 May; 31(5):2187-94. PubMed ID: 24676527 [TBL] [Abstract][Full Text] [Related]
57. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Kim SY; Kim HP; Kim YJ; Oh DY; Im SA; Lee D; Jong HS; Kim TY; Bang YJ Int J Oncol; 2008 Jan; 32(1):89-95. PubMed ID: 18097546 [TBL] [Abstract][Full Text] [Related]
58. Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition. Jin MH; Nam AR; Park JE; Bang JH; Bang YJ; Oh DY Mol Cancer Ther; 2017 Jun; 16(6):1145-1154. PubMed ID: 28223426 [TBL] [Abstract][Full Text] [Related]
59. The Antioxidant Alpha-Lipoic Acid Inhibits Proliferation and Invasion of Human Gastric Cancer Cells via Suppression of STAT3-Mediated MUC4 Gene Expression. Yang Y; Fang E; Luo J; Wu H; Jiang Y; Liu Y; Tong S; Wang Z; Zhou R; Tong Q Oxid Med Cell Longev; 2019; 2019():3643715. PubMed ID: 31915505 [TBL] [Abstract][Full Text] [Related]
60. The sensitivity of gastric cancer to trastuzumab is regulated by the miR-223/FBXW7 pathway. Eto K; Iwatsuki M; Watanabe M; Ishimoto T; Ida S; Imamura Y; Iwagami S; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Baba H Int J Cancer; 2015 Apr; 136(7):1537-45. PubMed ID: 25159729 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]